Nakagawa Kei, Katayose Yu, Unno Michiaki
Dept. of Surgery, Tohoku University Graduate School of Medicine, Japan.
Gan To Kagaku Ryoho. 2012 Nov;39(12):1945-7.
We performed a clinical trial of neoadjuvant chemoradiation therapy for cholangiocarcinoma with a preoperative diagnoses of clinical Stage III and IV. We examined the effect of preoperative chemoradiation for cStage II bile duct cancer. From 2008 until 2011, 75 cases were compared in terms of the preoperative diagnosis and pathological diagnosis of cholangiocarcinoma in our department. Additionally, 19 cases had been diagnosed as cStage II. However, 12 cases were higher than pStage III in their pathological diagnosis. We did not obtain pCur A in only 12 cases(63%). On the other hand, we obtained HM0, DM0, EM0, and pCur A in 5 patients with cStage II cholangiocarcinoma who underwent preoperative chemoradiation therapy. The neoadjuvant chemoradiation therapy for cholangiocarcinoma may control local cancer progression, thereby improving the surgical results of cStage II cholangiocarcinoma in this study.
我们对术前诊断为临床III期和IV期的胆管癌患者进行了新辅助放化疗的临床试验。我们研究了术前放化疗对cII期胆管癌的疗效。2008年至2011年,我们科室对75例胆管癌患者的术前诊断和病理诊断进行了比较。此外,有19例被诊断为cII期。然而,其中12例患者的病理诊断高于pIII期。仅12例患者(63%)未获得pCur A。另一方面,5例接受术前放化疗的cII期胆管癌患者获得了HM0、DM0、EM0和pCur A。在本研究中,胆管癌的新辅助放化疗可能控制局部癌症进展,从而改善cII期胆管癌的手术效果。